Actively Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Led by Arvinas Inc. · Updated on 2026-02-10
255
Participants Needed
17
Research Sites
181 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
CONDITIONS
Official Title
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have relapsed or refractory non-Hodgkin lymphoma with at least two prior systemic therapies including rituximab, or histologically confirmed angioimmunoblastic T-cell lymphoma that has recurred or progressed
- Have relapsed or refractory diffuse large B-cell lymphoma or large B-cell lymphoma arising from follicular lymphoma with at least two prior systemic therapies
- Have at least one measurable lesion larger than 1.5 cm for nodal or larger than 1.0 cm for extranodal
- Eastern Cooperative Oncology Group performance status of 0 or 1 (ECOG 2 allowed for secondary CNS lymphoma in Part A)
- Adequate bone marrow function
- Adequate kidney function
- Adequate liver function
You will not qualify if you...
- History of peripheral eosinophilia, hypereosinophilic syndrome, organ-specific eosinophilic disorder, or drug reaction with eosinophilia and systemic symptoms
- Prior allogeneic stem cell transplant or solid organ transplant
- Any other active malignancy within 3 years except treated basal cell or squamous cell skin cancer, melanoma in situ, carcinoma in situ of breast or cervix, or prostate cancer under active surveillance
- History in past 6 months of myocardial infarction, long QT syndrome, serious arrhythmias, third-degree AV block, unstable angina, coronary or peripheral artery bypass graft, symptomatic congestive heart failure (NYHA Class III or IV), cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, or other significant thromboembolic disease
- Active inflammatory gastrointestinal disease, chronic diarrhea, previous gastric resection, or lap band surgery
- Uncontrolled hypertension despite optimal treatment
- History of myocarditis
- Inability to comply with prohibited treatments
- Abnormal ECG that may affect safety or study results
- Cardiac ejection fraction less than 45%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
Clinical Trial Site
New Haven, Connecticut, United States, 06510
Actively Recruiting
2
Clinical Trial Site
Detroit, Michigan, United States, 48201
Actively Recruiting
3
Clinical Trial Site
New Brunswick, New Jersey, United States, 10065
Actively Recruiting
4
Clinical Trial Site
New York, New York, United States, 10016
Actively Recruiting
5
Clinical Trial Site
New York, New York, United States, 10021
Actively Recruiting
6
Clinical Trial Site
Cleveland, Ohio, United States, 44122
Actively Recruiting
7
Clinical Trial Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
8
Clinical Trial Site
Houston, Texas, United States, 77030
Actively Recruiting
9
Clinical Trial Site
Toronto, Ontario, Canada, M5G 1Z5
Actively Recruiting
10
Clinical Trial Site
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
11
Clinical Trial Site
Copenhagen, Denmark, 2100
Actively Recruiting
12
Clinical Trial Site
Odense C, Denmark, 5000
Actively Recruiting
13
Clinical Trial Site
El Palmar, Murcia, Spain, 30120
Actively Recruiting
14
Clinical Trial Site
Pamplona, Navarre, Spain, 31008
Actively Recruiting
15
Clinical Trial Site
Barcelona, Spain, 8908
Actively Recruiting
16
Clinical Trial Site
Madrid, Spain, 28050
Actively Recruiting
17
Clinical Trial Site
Salamanca, Spain, 37007
Actively Recruiting
Research Team
A
Arvinas Operations, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here